Showing results (71-80 of 83) with videos related to

Sort By:
Pageof 9
Cancers|May 28, 2022
Adverse Events in 1406 Patients Receiving 13,780 Cycles of Azacitidine within the Austrian Registry of Hypomethylating Agents-A Prospective Cohort Study of the AGMT Study-GroupMichael Leisch, Michael Pfeilstöcker, Reinhard Stauder, et al.
Haematologica|January 22, 2026
Real-world effectiveness and safety of belantamab mafodotin monotherapy in patients with relapsed/refractory multiple myeloma treated in EuropeMichele Cavo, Fredrik Schjesvold, Meletios Dimopoulos, et al.
Ejhaem|June 19, 2024
QoL during KTd or KRd induction followed by K maintenance or observation in transplant noneligible patients with newly diagnosed multiple myeloma: Longitudinal and cross-sectional analysis of the randomized AGMT 02 studyHeinz Ludwig, Thomas Melchardt, Ilvy Schweitzer, et al.
Transplantation and Cellular Therapy|July 2, 2026
Impact of Disease Biology and Bridging Strategy on Outcomes After CAR-T Cell Therapy in Relapsed/Refractory Multiple MyelomaIrene Strassl, Alexander Nikoloudis, Lina Zoe Ruesing, et al.
American Journal of Hematology|March 1, 2024
Randomized comparison between KTd and KRd induction therapy followed by maintenance therapy with K or observation in transplant-ineligible patients with newly diagnosed multiple myelomaHeinz Ludwig, Thomas Melchardt, Siegfried Sormann, et al.
American Journal of Hematology|August 7, 2023
Cox proportional hazards deep neural network identifies peripheral blood complete remission to be at least equivalent to morphologic complete remission in predicting outcomes of patients treated with azacitidine-A prospective cohort study by the AGMTLisa Pleyer, Marc Vaisband, Manuel Drost, et al.
The Lancet. Haematology|July 5, 2016
Rituximab maintenance versus observation alone in patients with chronic lymphocytic leukaemia who respond to first-line or second-line rituximab-containing chemoimmunotherapy: final results of the AGMT CLL-8a Mabtenance randomised trialRichard Greil, Petra Obrtlíková, Lukáš Smolej, et al.
Cancer Medicine|March 20, 2019
Rituximab maintenance overcomes the negative prognostic factor of obesity in CLL: Subgroup analysis of the international randomized AGMT CLL-8a mabtenance trialAlexander Egle, Thomas Melchardt, Petra Obrtlíková, et al.
Blood Advances|April 16, 2025
Outcomes of bispecific antibody therapy after CAR T-cell failure in relapsed/refractory large B-cell lymphomaEvgenii Shumilov, Julia Katharina Scholz, Maximilian Seib, et al.
Blood Advances|December 11, 2024
Safety and Efficacy of Glofitamab for Relapsed/Refractory Large B-Cell Lymphoma in a Multinational Real-World StudyEvgenii Shumilov, Rebecca Wurm-Kuczera, Andrea Kerkhoff, et al.
Pageof 9